Modafinil: Preclinical, clinical, and post-marketing surveillance - A review of abuse liability issues

Annals of Clinical Psychiatry

Volumn 16, Issue 2, 2004, Pages 101-109

  Myrick, Hugh ^a,b,c   Malcolm, Robert ^a   Taylor, Brent ^a   LaRowe, Steven ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Addiction; Modafinil; Substance abuse

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALPHA ADRENERGIC RECEPTOR; AMFEBUTAMONE; AMPHETAMINE; CAFFEINE; COCAINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DEXAMPHETAMINE; DOPAMINE; DOPAMINE TRANSPORTER; EPHEDRINE; ETHINYLESTRADIOL; GLUTAMIC ACID; HALOPERIDOL; METHYLPHENIDATE; MODAFINIL; PHENOXYBENZAMINE; PRAZOSIN; PROTEIN C FOS; RESERPINE; TRIAZOLAM;

AKINESIA; ATTENTION DEFICIT DISORDER; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; FOOD AND DRUG ADMINISTRATION; HEART PALPITATION; HUMAN; MEDICAL LIABILITY; NARCOLEPSY; NERVOUSNESS; NEUROPROTECTION; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; SUBSTANCE ABUSE;

BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; NARCOLEPSY; PRODUCT SURVEILLANCE, POSTMARKETING; SUBSTANCE-RELATED DISORDERS;

EID: 4143088220     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1080/10401230490453743     Document Type: Review

References (44)

1. Duteil J, Rambert FA, Pesssonnier J, Hermant JF, Gombert R, Assous E. Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil: studies with experimental animals. Eur J. Pharmacol 1990; 180:49-58.
2. Simon P, Hemet C, Ramassamy C, Costentin J. Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol 1995; 4:509-514.
3. Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther 1997; 283(2), 757-769.
4. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 1998; 54(5):1166-1175.
5. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention-deficithyperactivity disorder in adults. J Child Adolesc Psychopharmacol 2000; 10(4):311-320.
6. Rugino TA, Copley TC. Effect of modafinil in children with attention-deficit/hyperactivity disorder: An open-label study. J Am Acad Child Adolesc Psychiatry 2001; 40(2):230-235.
7. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000; 61(5):378-381.
8. Kaufman KR, Menza MA, Fitzsimmons A. Modafinil monotherapy in depression. Eur Psychiatry 2002; 17(3):167-169.
9. Kingshott RN, Vennelle M, Coleman EL, Engleman HM, Mackay TW, Douglas NJ. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hyopnea syndrome. Am J Respir Crit Care Med 2001; 163:918-923.
10. Pack AI, Black JE, Schwartz JR, Matheson JK. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001; 163:918-923.
11. Black JE, Douglas NJ, Earl CQ, Modafinil OSA Study Group. Efficacy and safety of modafinil as adjunctive therapy for excessive sleepiness associated with obstructive sleep apnea (abstract). Sleep 2002: 25(Suppl 1): A22.
12. Hogl B, Saleto M, Brandauer E, Glatzl S, Frauscher B, Seppi K, Ulmer H, Wenning G, Poewe W. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002: 25(8):905-909.
13. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003; 13(3):287-293.
14. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two center phase 2 study. J Neurol Neurosurg Psychiatry 2002; (2):179-183.
15. Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 2002; 249(8): 983-987.
16. Provigil® (modafinil) Package Insert: Cephalon, Inc., West Chester, PA, 2002. Available at: http://www.provigil.com
17. Robertson P Jr., Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003; 42(2):123-137.
18. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA 1996; 98(24):14128-14133.
19. Engber TM, Koury EJ, Dennis SA, Miller MS, Contreras PC, Bhat RV. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett 1998; 241(2-3):95-98.
20. Scammel TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during Modafinil-induced wakefulness. Journal of Neuroscience 2000; 20(22):8620-8628.
21. Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994; 17(5):436-437.
22. Roth BL. Personal Communication. July 10, 2003.
23. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001; 21(5):1787-1794.
24. Stone EA, Cotecchia S, Lin Y, Quartermain D. Role of brain alphalB adrenoreceptors in modafinil-induced behavioral activity. Synapse 2002; 42:269-270.
25. Ferraro L, Antonelli T, O'Connor WT, et al. Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry 1997; 42:1181-1183.
26. Perez de la Mora M, Aguilar-Garcia A, Ramon-Frias T, et al. Effects of the vigilant-promoting drug modafinil on the synthesis of GABA and glutamate in slices of rat hypothalamus. Neuroscience Letter 1999; 259:181-185.
27. Antonelli T, Ferraro L, Hillion J, Tomasini MC, Rambert FA, Fuxe K. Modafinil prevents glutamate cytotoxicity in cultured cortical neurons. Neuroreport 1998; 9(18):4209-4213.
28. Jenner P, Zeng BY, Smith LA, et al. Antiparkinsonian and neuroprotective effects of modafinil in the MPTP-treated common marmoset. Exp Brain Res. 2000; 133(2):178-188.
29. Davidson C, Gow AJ, Lee TH, Ellinwood EH. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 2001; 36(1):1-22.
30. McCann UD, Eligulashvili V, Ricaurte, GA: (+/-) 3,4- Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 2000; 42(1):11-16.
31. Gold LH, Balster RL. Evaluation of the cocaine like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacol 1996; 126:286-292.
32. Deroche-Gamonet V, Darnaudery M, Bruins-Slot L, Piat F, Le Moal M, Piazza PV. Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology (Berl) 2002; 161(4):387-395.
33. Vocci FJ Jr. The necessity and utility of abuse liability evaluations in human subjects: the FDA perspective. Testing for abuse liability of drugs in humans. Bethesda, Md: National Institute on Drug Abuse; 1989 NIDA Research Monograph 92:7-20. Available at: http://www.drugabuse.gov/pdf/monographs/ download92.html
34. Warot D, Corruble E, Payan C, Weil JS, Puech AJ. Subjective effects of modafinil, a new centeral adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine, and placebo. Eur Psychiatry 1993; 8:201-208.
35. Jasinski DR. Distinguishing modafinil from methylphenidate in a study of abuse potential: gender comparison. Presented at the Annual Meeting of the College on Problems of Drug Dependence, June 14-19, 1997, Nashville, TN.
36. Jasinski DR, Kovacevic-Ristanovi ĆR. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clinical Neuropharmacology 2000; 23(3): 149-156.
37. Rush CR, Kelly TH, Hays LR, Baker RW, Wooten AF. Acute behavioral and physiological effects of modafinil in drug abusers. Behavioural Pharmacology 2002; 13(2): 105-115.
38. Rush CR, Kelly TH, Hays LR, Wooten AF. Discriminative-stimulus effects of modafinil in cocaine-trained humans. Drug and Alcohol Dependence 2002; 67: 311-322.
39. Dackis CA, Lynch KG, Yu E, et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003; 70(1):29-37.
40. Westensten NJ, Belenky G, Kautz MA, Thorne DR, Reichardt RM, Balkin TJ. Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine. Psychopharmacology 2002; 159:238-247.
41. Malcolm R, Devane L, Donovan J, et al. Modafinil dampens multiple aspects of intravenous cocaine high. Unpublished. Presented June 15, 2003; College of Problems of Drug Dependence, Bal Harbour, FL.
42. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. Journal of Psychopharmacology 2000; 14(1):53-60.
43. Galloway G. Personal Communication. June 15, 2003.
44. Malcolm R, Book S, Moak D, DeVane L, Czepowicz V. Clinical applications of modafinil in stimulant abusers: low abuse potential. Am J Addictions 2002; 11:247-249.